Alnylam Pharmaceuticals (ALNY) Earnings Date, Estimates & Call Transcripts $300.61 +2.13 (+0.71%) As of 03:51 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Alnylam Pharmaceuticals Earnings Summary Alnylam Pharmaceuticals released Q1 2026 earnings on April 30, 2026, reporting an EPS of $1.99, which topped analysts' consensus estimates of $0.87 by $1.12. Quarterly revenue rose 96.4% year-over-year to $1.17 billion, above the consensus estimate of $1.12 billion. With a trailing EPS of $3.66 and a P/E Ratio of 82.33, Alnylam Pharmaceuticals' earnings are expected to grow 39.54% next year, from $7.36 to $10.27 per share. Upcoming Q2 Earnings DateJul. 30Before Market OpensEstimatedConsensus EPS (Apr. 30) $0.87 Actual EPS (Apr. 30) $1.99 Beat By $1.12 Actual Revenue (Apr. 30) $1.17BQ1 2026 Earnings ResourcesQ1 2026 Earnings ReportConference Call Transcript & Audio Slide Deck Press Release (8-K) Quarterly Report (10-Q)ALNY Upcoming EarningsAlnylam Pharmaceuticals' next earnings date is estimated for Thursday, July 30, 2026, based on past reporting schedules. Slide DeckFull Screen Slide DeckPowered by Get Alnylam Pharmaceuticals Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alnylam Pharmaceuticals and other key companies, straight to your inbox. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Charts & View Estimated and Actual Earnings DataALNY Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.ALNY Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Alnylam Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateRevenue EstimateCompany Revenue GuidanceQ1 20261-$0.05-$0.05-$0.05Q2 20262-$0.15$1.43$0.64Q3 20262$0.07$2.16$1.12Q4 20262-$0.08$2.78$1.35 Alnylam Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 7/30/2026(Estimated)--------4/30/2026Q1 2026$0.8720$1.99+$1.1180$1.51$1.12B$1.17B2/12/2026Q4 2025$1.43$1.25 -$0.18$0.82$1.16B$1.10B7/31/2025Q2 2025-$0.54$0.32+$0.86-$0.51$633.54M$773.69M5/1/2025Q1 2025-$0.37-$0.44 -$0.07-$0.44$584.32M$594.19M2/13/2025Q4 2024-$0.62-$0.65 -$0.03-$0.65$580.62M$593.17M10/31/2024Q3 2024-$0.51-$0.87 -$0.36-$0.87$532.91M$500.90M8/1/2024Q2 2024-$0.74-$0.13+$0.61-$0.13$447.22M$659.83M Data powered by Fiscal.ai. Alnylam Pharmaceuticals Earnings - Frequently Asked Questions When is Alnylam Pharmaceuticals' earnings date? Alnylam Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, July 30th, 2026 based off last year's report dates. Learn more on ALNY's earnings history. What guidance has Alnylam Pharmaceuticals issued on next quarter's earnings? Alnylam Pharmaceuticals updated its FY 2026 earnings guidance on Thursday, April, 30th. The company issued revenue guidance of $5.3 billion-$5.8 billion, compared to the consensus revenue estimate of $5.6 billion. Did Alnylam Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) reported $1.99 earnings per share (EPS) to beat the analysts' consensus estimate of $0.87 by $1.12. Learn more on analysts' earnings estimate vs. ALNY's actual earnings. How can I listen to Alnylam Pharmaceuticals' earnings conference call? The conference call for Alnylam Pharmaceuticals' latest earnings report can be listened to online. Listen to Conference Call How can I read Alnylam Pharmaceuticals' conference call transcript? The conference call transcript for Alnylam Pharmaceuticals' latest earnings report can be read online. Read Transcript How much revenue does Alnylam Pharmaceuticals generate each year? Alnylam Pharmaceuticals (NASDAQ:ALNY) has a recorded annual revenue of $3.71 billion. How much profit does Alnylam Pharmaceuticals generate each year? Alnylam Pharmaceuticals (NASDAQ:ALNY) has a recorded net income of $313.75 million. ALNY has generated $3.66 earnings per share over the last four quarters. What is Alnylam Pharmaceuticals' price-to-earnings ratio? Alnylam Pharmaceuticals (NASDAQ:ALNY) has a trailing price-to-earnings ratio of 82.12 and a forward price-to-earnings ratio of 40.75. What is Alnylam Pharmaceuticals' EPS forecast for next year? Alnylam Pharmaceuticals' earnings are expected to grow from $7.36 per share to $10.27 per share in the next year, which is a 39.54% increase. More Earnings Resources from MarketBeat Related Companies Vertex Pharmaceuticals Earnings Date Regeneron Pharmaceuticals Earnings Date Biogen Earnings Date United Therapeutics Earnings Date Incyte Earnings Date Neurocrine Biosciences Earnings Date Ionis Pharmaceuticals Earnings Date Exelixis Earnings Date Madrigal Pharmaceuticals Earnings Date BioMarin Pharmaceutical Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles NVIDIA Price Pullback? Don’t Count on It, Business Is AcceleratingMeta Platforms 10% Layoff Raises a Bigger Question About AI SpendingTarget Shows Strengths, But Analysts Want to See MoreFreight Boom: The Hormuz Blockade PaydayTJX Companies Fires on All Cylinders With 9% Revenue GrowthAnalog Devices Provides Much-Needed Pullback: How Low Can It Go?USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms This page (NASDAQ:ALNY) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alnylam Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alnylam Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
